We are live on
!
Find out more
FLAM
First Light Asset Management Portfolio holdings
AUM
$1.12B
1-Year Est. Return
114.45%
This Fund
S&P 500
This Quarter
Est. Return
-4.94%
1 Year Est. Return
+114.45%
3 Year Est. Return
+266.49%
5 Year Est. Return
+454.92%
10 Year Est. Return
+8,470.94%
AUM
$662M
AUM Growth
-$58.7M
(-8.2%)
Cap. Flow
-$11.3M
Cap. Flow
% of AUM
-1.71%
Top 10 Holdings %
Top 10 Hldgs %
49.89%
Holding
81
New
8
Increased
13
Reduced
33
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Insmed
INSM
|
+$25M |
| 2 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$21.4M |
| 3 |
AMRN
Amarin Corp
AMRN
|
+$16M |
| 4 |
TRHC
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
|
+$11.2M |
| 5 |
Halozyme
HALO
|
+$10.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARRY
Array Biopharma Inc
ARRY
|
+$56.2M |
| 2 |
Nektar Therapeutics
NKTR
|
+$25.4M |
| 3 |
AERI
Aerie Pharmaceuticals
AERI
|
+$14.1M |
| 4 |
Viatris
VTRS
|
+$10.9M |
| 5 |
Xencor
XNCR
|
+$6.54M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 68.09% |
| 2 | Communication Services | 8.27% |
| 3 | Industrials | 1.62% |
| 4 | Energy | 0.92% |
| 5 | Financials | 0.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
OXFD
1
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $61.9M | 9.35% |
3,719,291
+578,944
| +18% | +$8.01M |
|
|
MODN
2
DELISTED
MODEL N, INC.
MODN
| $54.7M | 8.27% |
1,970,044
-208,476
| -10% | -$5.18M |
|
3
Omnicell
OMCL
$1.61B
| $32.9M | 4.98% |
455,737
+124,275
| +37% | +$9.12M |
|
|
MYOK
4
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $27.8M | 4.21% |
533,944
-4,055
| -0.8% | -$216K |
|
5
AtriCure
ATRC
$1.92B
| $27.6M | 4.17% |
1,105,709
-6,031
| -0.5% | -$172K |
|
|
6
Halozyme
HALO
$9.79B
| $26.1M | 3.95% |
1,682,745
+614,932
| +58% | +$10.1M |
|
7
NeoGenomics
NEO
$1.96B
| $25.2M | 3.81% |
1,319,746
-5,836
| -0.4% | -$137K |
|
|
8
Insmed
INSM
$21.4B
| $22.8M | 3.45% |
+1,294,743
| New | +$25M |
|
|
SPNE
9
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $22.6M | 3.42% |
1,852,556
+51,559
| +3% | +$622K |
|
|
XENT
10
DELISTED
Intersect ENT, Inc
XENT
| $20.7M | 3.13% |
1,216,122
+547,229
| +82% | +$9.96M |
|
|
PTLA
11
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $20.5M | 3.1% |
+764,096
| New | +$21.4M |
|
12
Heron Therapeutics
HRTX
$93.9M
| $20.2M | 3.05% |
1,091,110
-7,613
| -0.7% | -$140K |
|
13
Ionis Pharmaceuticals
IONS
$8.6B
| $19.4M | 2.94% |
324,649
-2,483
| -0.8% | -$162K |
|
|
IMMU
14
DELISTED
Immunomedics Inc
IMMU
| $16.6M | 2.51% |
1,250,536
+27,053
| +2% | +$398K |
|
15
Codexis
CDXS
$151M
| $16.4M | 2.48% |
1,198,452
-7,071
| -0.6% | -$111K |
|
|
AMRN
16
Amarin Corp
AMRN
$299M
| $13.9M | 2.11% |
+45,942
| New | +$16M |
|
17
SI-BONE Inc
SIBN
$788M
| $11.4M | 1.73% |
645,982
-5,337
| -0.8% | -$102K |
|
|
18
Xencor
XNCR
$1.5B
| $11.3M | 1.71% |
335,444
-163,900
| -33% | -$6.54M |
|
|
ELGX
19
DELISTED
Endologix Inc
ELGX
| $11.3M | 1.71% |
2,844,317
+381,869
| +16% | +$2.22M |
|
20
Agios Pharmaceuticals
AGIO
$1.79B
| $10.8M | 1.63% |
332,442
+84,545
| +34% | +$3.5M |
|
|
TRHC
21
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
| $10.7M | 1.62% |
+195,347
| New | +$11.2M |
|
22
Veracyte
VCYT
$3.7B
| $9.86M | 1.49% |
410,925
-178,174
| -30% | -$4.74M |
|
|
VAPO
23
DELISTED
Vapotherm, Inc. Common Stock
VAPO
| $9.7M | 1.47% |
127,967
+65,846
| +106% | +$7.65M |
|
|
ARNA
24
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $8.73M | 1.32% |
190,838
+146,134
| +327% | +$8.21M |
|
25
Tandem Diabetes Care
TNDM
$1.34B
| $8.04M | 1.22% |
136,328
-537
| -0.4% | -$34.3K |
|
Similar funds
AIM
MTCM
CNC
C
RIM
CT
SL
HH
First Light Asset Management's Q3 2019 Portfolio in Review
As of Q3 2019, First Light Asset Management held 81 positions worth $662M, down 8.2% from $720M the previous quarter. Its ten largest holdings account for 50% of the portfolio.
First Light Asset Management's Q3 2019 filing shows 8 new, 13 increased, 33 reduced and 10 closed positions. Its largest new stake was Insmed: 1,294,743 shares worth $22.8M. The largest sale was Array Biopharma Inc, an estimated $56.2M.
By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 74% a quarter earlier, followed by Communication Services and Industrials.
- First Light Asset Management's largest Q3 2019 buy was Insmed: 1,294,743 shares worth $22.8M.
- First Light Asset Management added most to Halozyme in Q3 2019, an estimated $10.1M increase.
- First Light Asset Management's biggest Q3 2019 reduction was Viatris, cutting an estimated $10.9M.
- First Light Asset Management fully exited Array Biopharma Inc in Q3 2019, selling an estimated $56.2M.
- First Light Asset Management's ten largest holdings make up 50% of its $662M portfolio in Q3 2019.
- First Light Asset Management opened 8 new positions and closed 10 in Q3 2019.
- First Light Asset Management's portfolio value fell 8.2% quarter-over-quarter to $662M.
Based on First Light Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.